Pharsight

Pf Prism Cv patents expiration

1. Bosulif patents expiration

BOSULIF's oppositions filed in EPO
BOSULIF IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6002008 PF PRISM CV Substituted 3-cyano quinolines
Mar, 2018

(6 years ago)

USRE42376 PF PRISM CV Substituted 3-cyanoquinolines
Apr, 2024

(2 months ago)

US7767678 PF PRISM CV Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same
Nov, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6002008 PF PRISM CV Substituted 3-cyano quinolines
Mar, 2018

(6 years ago)

USRE42376

(Pediatric)

PF PRISM CV Substituted 3-cyanoquinolines
Oct, 2024

(3 months from now)

US7417148 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Dec, 2025

(1 year, 5 months from now)

US7919625 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Dec, 2025

(1 year, 5 months from now)

US7417148

(Pediatric)

PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Jun, 2026

(1 year, 11 months from now)

US7919625

(Pediatric)

PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Jun, 2026

(1 year, 11 months from now)

US7767678

(Pediatric)

PF PRISM CV Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same
May, 2027

(2 years from now)

US11103497 PF PRISM CV Treatment of imatinib resistant leukemia
Feb, 2034

(9 years from now)

US11103497

(Pediatric)

PF PRISM CV Treatment of imatinib resistant leukemia
Aug, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-163) Dec 19, 2024
Orphan Drug Exclusivity(ODE-444) Sep 26, 2030
New Indication(I-923) Sep 26, 2026
Pediatric Exclusivity(PED) Mar 26, 2027
New Indication(I-759) Dec 19, 2020
Orphan Drug Exclusivity(ODE) Sep 04, 2019
Orphan Drug Exclusivity(ODE-30) Sep 04, 2019
New Chemical Entity Exclusivity(NCE) Sep 04, 2017

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

NCE-1 date: 26 March, 2026

Market Authorisation Date: 04 September, 2012

Treatment: A method of treating a neoplasm; A method of treating patients with accelerated, or blast phase ph+ cml with resistance or intolerance to prior therapy; A method for treating a bcrabl positive leukemi...

Dosage: TABLET;ORAL; CAPSULE;ORAL

How can I launch a generic of BOSULIF before it's drug patent expiration?
More Information on Dosage

BOSULIF family patents

Family Patents

2. Chantix patents expiration

CHANTIX IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6410550 PF PRISM CV Aryl fused azapolycyclic compounds
May, 2020

(4 years ago)

US6410550

(Pediatric)

PF PRISM CV Aryl fused azapolycyclic compounds
Nov, 2020

(3 years ago)

US6890927 PF PRISM CV Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
May, 2022

(2 years ago)

US7265119 PF PRISM CV Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
Aug, 2022

(1 year, 10 months ago)

US6890927

(Pediatric)

PF PRISM CV Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
Nov, 2022

(1 year, 7 months ago)

US7265119

(Pediatric)

PF PRISM CV Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
Feb, 2023

(1 year, 4 months ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-192) Dec 16, 2019
Pediatric Exclusivity(PED) Aug 22, 2022
M(M-183) Aug 12, 2019
M(M-144) Oct 15, 2017
M(M-143) Oct 15, 2017
M(M-237) Feb 22, 2022
M(M-105) Jul 22, 2014

Drugs and Companies using VARENICLINE TARTRATE ingredient

Market Authorisation Date: 10 May, 2006

Treatment: Aid to smoking cessation

Dosage: TABLET;ORAL

How can I launch a generic of CHANTIX before it's drug patent expiration?
More Information on Dosage

CHANTIX family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Inlyta patents expiration

INLYTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6534524 PF PRISM CV Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Apr, 2025

(10 months from now)

US8791140 PF PRISM CV Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
Dec, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7141581 PF PRISM CV Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Jun, 2020

(3 years ago)

US10570202 PF PRISM CV Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
Feb, 2035

(10 years from now)

US10869924 PF PRISM CV PD-L1 antagonist combination treatments
Jan, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 27, 2017

Drugs and Companies using AXITINIB ingredient

NCE-1 date: 28 January, 2016

Market Authorisation Date: 27 January, 2012

Treatment: Treatment of renal cell carcinoma; In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-li...

Dosage: TABLET;ORAL

How can I launch a generic of INLYTA before it's drug patent expiration?
More Information on Dosage

INLYTA family patents

Family Patents

4. Pristiq patents expiration

PRISTIQ's oppositions filed in EPO
PRISTIQ IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6673838 PF PRISM CV Succinate salt of O-desmethyl-venlafaxine
Mar, 2022

(2 years ago)

US8269040 PF PRISM CV Derivatives of venlafaxine and methods of preparing and using the same
Jul, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6673838 PF PRISM CV Succinate salt of O-desmethyl-venlafaxine
Feb, 2022

(2 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-675) Feb 14, 2016
M(M-222) Feb 06, 2021
New Chemical Entity Exclusivity(NCE) Mar 01, 2013

Drugs and Companies using DESVENLAFAXINE SUCCINATE ingredient

NCE-1 date: 01 March, 2012

Market Authorisation Date: 20 August, 2014

Treatment: For the approved uses and conditions of use, including depression; Maintenance treatment of major depressive disorder (mdd)

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of PRISTIQ before it's drug patent expiration?
More Information on Dosage

PRISTIQ family patents

Family Patents

5. Rapamune patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5403833

(Pediatric)

PF PRISM CV Methods of inhibiting transplant rejecton in mammals using rapamycin and derivatives and prodrugs thereof
Oct, 2012

(11 years ago)

US5100899 PF PRISM CV Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
Jul, 2013

(10 years ago)

US5536729 PF PRISM CV Rapamycin formulations for oral administration
Sep, 2013

(10 years ago)

US5100899

(Pediatric)

PF PRISM CV Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
Jan, 2014

(10 years ago)

US5536729

(Pediatric)

PF PRISM CV Rapamycin formulations for oral administration
Mar, 2014

(10 years ago)

US5989591 PF PRISM CV Rapamycin formulations for oral administration
Mar, 2018

(6 years ago)

US5989591

(Pediatric)

PF PRISM CV Rapamycin formulations for oral administration
Sep, 2018

(5 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) May 28, 2022
Orphan Drug Exclusivity(ODE-92) May 28, 2022

Drugs and Companies using SIROLIMUS ingredient

Market Authorisation Date: 15 September, 1999

Treatment: Inhibiting transplant rejection using rapamycin (sirolimus)

Dosage: SOLUTION;ORAL; TABLET;ORAL

How can I launch a generic of RAPAMUNE before it's drug patent expiration?
More Information on Dosage

RAPAMUNE family patents

Family Patents

6. Torisel patents expiration

TORISEL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44768 PF PRISM CV Rapamycin hydroxyesters
Feb, 2019

(5 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5362718 PF PRISM CV Rapamycin hydroxyesters
Apr, 2014

(10 years ago)

US5362718

(Pediatric)

PF PRISM CV Rapamycin hydroxyesters
Oct, 2014

(9 years ago)

USRE44768

(Pediatric)

PF PRISM CV Rapamycin hydroxyesters
Aug, 2019

(4 years ago)

US8455539 PF PRISM CV CCI-779 concentrate formulations
Jul, 2023

(10 months ago)

US8722700 PF PRISM CV CCI-779 formulations for parenteral administration
Jul, 2023

(10 months ago)

US8299116 PF PRISM CV CCI-779 concentrate formulations
Jul, 2023

(10 months ago)

US8455539

(Pediatric)

PF PRISM CV CCI-779 concentrate formulations
Jan, 2024

(4 months ago)

US8299116

(Pediatric)

PF PRISM CV CCI-779 concentrate formulations
Jan, 2024

(4 months ago)

US8722700

(Pediatric)

PF PRISM CV CCI-779 formulations for parenteral administration
Jan, 2024

(4 months ago)

US8026276 PF PRISM CV Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant
Jan, 2026

(1 year, 7 months from now)

US8026276

(Pediatric)

PF PRISM CV Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant
Jul, 2026

(2 years from now)

US8791097 PF PRISM CV Anti-tumor activity of CCI-779 in papillary renal cell cancer
May, 2032

(7 years from now)

US8791097

(Pediatric)

PF PRISM CV Anti-tumor activity of CCI-779 in papillary renal cell cancer
Nov, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-61) May 30, 2015
M(M-92) Jul 09, 2013
Orphan Drug Exclusivity(ODE) May 30, 2014
M(M-91) Apr 26, 2013
Pediatric Exclusivity(PED) Jan 09, 2014

Drugs and Companies using TEMSIROLIMUS ingredient

Market Authorisation Date: 30 May, 2007

Treatment: Method of treating metastatic papillary renal cell carcinoma with temsirolimus.

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of TORISEL before it's drug patent expiration?
More Information on Dosage

TORISEL family patents

Family Patents

7. Tygacil patents expiration

TYGACIL's oppositions filed in EPO
TYGACIL IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE40086 PF PRISM CV Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines
Jun, 2013

(10 years ago)

USRE40183 PF PRISM CV 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
Apr, 2016

(8 years ago)

US9254328 PF PRISM CV Tigecycline compositions and methods of preparation
Mar, 2026

(1 year, 8 months from now)

US9694078 PF PRISM CV Tigecycline compositions and methods of preparation
Mar, 2026

(1 year, 8 months from now)

US10588975 PF PRISM CV Tigecycline compositions and methods of preparation
Mar, 2026

(1 year, 8 months from now)

US8975242 PF PRISM CV Tigecycline compositions and methods of preparation
Oct, 2028

(4 years from now)

US7879828 PF PRISM CV Tigecycline compositions and methods of preparation
Feb, 2029

(4 years from now)

US8372995 PF PRISM CV Crystalline solid forms of tigecycline and methods of preparing same
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-587) Mar 20, 2012
New Indication(I-588) Mar 20, 2012
New Indication(I-586) Mar 20, 2012

Drugs and Companies using TIGECYCLINE ingredient

Market Authorisation Date: 15 June, 2005

Treatment: Method of treating bacterial infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

TYGACIL family patents

Family Patents

8. Vfend patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5567817 PF PRISM CV Triazole antifungal agents
May, 2016

(8 years ago)

US6632803 PF PRISM CV Pharmaceutical formulations containing voriconazole
Jun, 2018

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jan 29, 2022

Drugs and Companies using VORICONAZOLE ingredient

Market Authorisation Date: 19 December, 2003

Treatment: Treatment of fungal infections

Dosage: FOR SUSPENSION;ORAL; INJECTABLE;INTRAVENOUS; TABLET;ORAL

How can I launch a generic of VFEND before it's drug patent expiration?
More Information on Dosage

VFEND family patents

Family Patents

9. Xalkori patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8785632 PF PRISM CV Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Mar, 2025

(8 months from now)

US7230098 PF PRISM CV Aminoheteroaryl compounds as protein kinase inhibitors
Aug, 2025

(1 year, 2 months from now)

US7858643 PF PRISM CV Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Oct, 2029

(5 years from now)

US8217057 PF PRISM CV Polymorphs of a c-MET/HGFR inhibitor
Nov, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7825137 PF PRISM CV Method of treating abnormal cell growth
May, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-852) Jan 14, 2024
New Indication(I-897) Jul 14, 2025

Drugs and Companies using CRIZOTINIB ingredient

Market Authorisation Date: 07 September, 2023

Treatment: Treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (alcl) that is anaplastic lymphoma kinase (alk)-positive

Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL

More Information on Dosage

XALKORI family patents

Family Patents

10. Xeljanz patents expiration

XELJANZ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7265221 PF PRISM CV Pyrrolo[2,3-d]pyrimidine compounds
Dec, 2020

(3 years ago)

US7301023 PF PRISM CV Chiral salt resolution
Dec, 2020

(3 years ago)

US6965027 PF PRISM CV Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
Mar, 2023

(1 year, 2 months ago)

USRE41783 PF PRISM CV Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(1 year, 5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7265221 PF PRISM CV Pyrrolo[2,3-d]pyrimidine compounds
Dec, 2020

(3 years ago)

US7842699 PF PRISM CV Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2020

(3 years ago)

US6956041 PF PRISM CV Pyrrolo[2,3-d]pyrimidine compounds
Dec, 2020

(3 years ago)

US7091208 PF PRISM CV Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2020

(3 years ago)

US7301023 PF PRISM CV Chiral salt resolution
May, 2022

(2 years ago)

US6965027 PF PRISM CV Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
Mar, 2023

(1 year, 2 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-879) Dec 14, 2024
New Patient Population(NPP) Sep 25, 2023
New Indication(I-761) Dec 14, 2020
M(M-135) Feb 21, 2017
New Indication(I-780) May 30, 2021
New Chemical Entity Exclusivity(NCE) Nov 06, 2017

Drugs and Companies using TOFACITINIB CITRATE ingredient

NCE-1 date: 06 November, 2016

Market Authorisation Date: 06 November, 2012

Treatment: Treatment of adult patients with moderately to severely active ulcerative colitis (uc); Treatment of rheumatoid arthritis

Dosage: TABLET;ORAL

How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage

XELJANZ family patents

Family Patents

11. Zmax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6068859 PF PRISM CV Controlled-release dosage forms of Azithromycin
May, 2017

(7 years ago)

US6268489 PF PRISM CV Azithromycin dihydrate
Jul, 2018

(5 years ago)

US6984403 PF PRISM CV Azithromycin dosage forms with reduced side effects
Feb, 2024

(4 months ago)

US7887844 PF PRISM CV Multiparticulate crystalline drug compositions having controlled release profiles
Feb, 2024

(4 months ago)

Drugs and Companies using AZITHROMYCIN ingredient

Market Authorisation Date: 10 June, 2005

Treatment: Method of treating bacterial infections

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

ZMAX family patents

Family Patents